Full Text:   <2785>

CLC number: R735.3

On-line Access: 2014-06-07

Received: 2013-10-08

Revision Accepted: 2014-02-26

Crosschecked: 2014-05-25

Cited: 3

Clicked: 5954

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2014 Vol.15 No.6 P.582-589

http://doi.org/10.1631/jzus.B1300258


HER-2 overexpression and survival in colorectal cancer: a meta-analysis*


Author(s):  Chao Li, Da-ren Liu, Long-yun Ye, Ling-na Huang, Sanjay Jaiswal, Xiao-wen Li, Hou-hong Wang, Li Chen

Affiliation(s):  . Department of Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310021, China

Corresponding email(s):   chenli_hz@yahoo.com

Key Words:  Human epidermal growth factor receptor 2 (HER-2), Colorectal cancer (CRC), Survival, Meta-analysis


Chao Li, Da-ren Liu, Long-yun Ye, Ling-na Huang, Sanjay Jaiswal, Xiao-wen Li, Hou-hong Wang, Li Chen. HER-2 overexpression and survival in colorectal cancer: a meta-analysis[J]. Journal of Zhejiang University Science B, 2014, 15(6): 582-589.

@article{title="HER-2 overexpression and survival in colorectal cancer: a meta-analysis",
author="Chao Li, Da-ren Liu, Long-yun Ye, Ling-na Huang, Sanjay Jaiswal, Xiao-wen Li, Hou-hong Wang, Li Chen",
journal="Journal of Zhejiang University Science B",
volume="15",
number="6",
pages="582-589",
year="2014",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1300258"
}

%0 Journal Article
%T HER-2 overexpression and survival in colorectal cancer: a meta-analysis
%A Chao Li
%A Da-ren Liu
%A Long-yun Ye
%A Ling-na Huang
%A Sanjay Jaiswal
%A Xiao-wen Li
%A Hou-hong Wang
%A Li Chen
%J Journal of Zhejiang University SCIENCE B
%V 15
%N 6
%P 582-589
%@ 1673-1581
%D 2014
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1300258

TY - JOUR
T1 - HER-2 overexpression and survival in colorectal cancer: a meta-analysis
A1 - Chao Li
A1 - Da-ren Liu
A1 - Long-yun Ye
A1 - Ling-na Huang
A1 - Sanjay Jaiswal
A1 - Xiao-wen Li
A1 - Hou-hong Wang
A1 - Li Chen
J0 - Journal of Zhejiang University Science B
VL - 15
IS - 6
SP - 582
EP - 589
%@ 1673-1581
Y1 - 2014
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1300258


Abstract: 
Objective: Numerous studies examining the relationship between human epidermal growth factor receptor 2 (HER-2) overexpression and survival in patients with colorectal cancer (CRC) have yielded controversial results. We therefore performed a meta-analysis more precisely to estimate its prognostic value. Methods: Published studies investigating the effect of HER-2 overexpression on CRC survival were identified; the hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were pooled in terms of disease-specific or overall survival. Results: Eleven studies were included in the meta-analysis. The pooled data showed that HER-2 overexpression was negatively related to CRC survival (HR=1.10, 95% CI: 0.77–1.44). Subgroup analyses regarding test method and study quality also demonstrated little association between HER-2 overexpression and CRC survival (HR=0.89, 95% CI: 0.50–1.29; HR=0.90, 95% CI: 0.43–1.37, respectively). Conclusions: Regardless of several limitations, our study suggested that HER-2 overexpression probably had little impact on CRC survival.

HER-2高表达与结直肠癌生存期关系的meta分析

研究目的:探讨人类表皮生长因子受体2(HER-2)的高表达与结直肠癌患者术后生存期的关系。
创新要点:采用meta分析的方法,精确地探讨HER-2高表达与结直肠癌患者生存期的关系,解决不同研究产生不同结论的矛盾。
研究方法:系统收集近20年来所有与HER-2表达和结直肠癌生存期关系相关文献,提取数据并计算与癌症或总体生存时间对应的危险比及其95%可信区间。
重要结论:HER-2高表达可能与结直肠癌患者术后生存时间无关(见图2)。

关键词:人类表皮生长因子受体2(HER-2);结直肠癌;生存期;Meta分析

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

References

[1] Akiyama, T., Sudo, C., Ogawara, H., 1986. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232(4758):1644-1646. 


[2] Baiocchi, G., Lopes, A., Coudry, R.A., 2009. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis, 24(9):1059-1068. 


[3] Bang, Y.J., van Cutsem, E., Feyereislova, A., 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376(9742):687-697. 


[4] Blok, E.J., Kuppen, P.J.K., van Leeuwen, J.E.M., 2013. Cytoplasmic overexpression of HER2: a key factor in colorectal cancer. Clin Med Insights Oncol, 7:41-51. 


[5] Chen, J., Li, Q., Wang, C., 2010. Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases. Ann Surg Oncol, 17(6):1555-1563. 


[6] Conradi, L.C., Styczen, H., Sprenger, T., 2013. Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol, 37(4):522-531. 


[7] Ferlay, J., Shin, H.R., Bray, F., 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127(12):2893-2917. 


[8] Gravalos, C., Jimeno, A., 2008. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 19(9):1523-1529. 


[9] Higgins, J.P., Thompson, S.G., Deeks, J.J., 2003. Measuring inconsistency in meta-analyses. BMJ, 327(7414):557-560. 


[10] Jesus, E.C., Matos, D., Artigiani, R., 2005. Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. Acta Cirurg Bras, 20(6):422-427. 


[11] Jorissen, R.N., Walker, F., Pouliot, N., 2003. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res, 284(1):31-53. 


[12] Kaptain, S., Tan, L.K., Chen, B., 2001. Her-2/neu and breast cancer. Diagn Mol Pathol, 10(3):139-152. 


[13] Kavanagh, D.O., Chambers, G., O'Grady, L., 2009. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?. BMC Cancer, 9:1


[14] Koeppen, H.K.W., Wright, B.D., Burt, A.D., 2001. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology, 38(2):96-104. 


[15] Li, Q., Wang, D., Li, J., 2011. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer, 11:277


[16] Lu, Y., Jingyan, G., Baorong, S., 2012. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Cancer Biomark, 11(5):219-226. 


[17] Mann, M., Sheng, H., Shao, J., 2001. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology, 120(7):1713-1719. 


[18] McKay, J.A., Loane, J.F., Ross, V.G., 2002. c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer, 86(4):568-573. 


[19] Osako, T., Miyahara, M., Uchino, S., 1998. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology, 55(6):548-555. 


[20] Park, D.I., Kang, M.S., Oh, S.J., 2007. Her-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis, 22(5):491-497. 


[21] Pazo Cid, R.A., Antn, A., 2013. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol, 85(3):350-362. 


[22] Rossi, H.A., Liu, Q., Banner, B., 2002. The prognostic value of invariant chain (II) and Her-2/neu expression in curatively resected colorectal cancer. Cancer J, 8(3):268-275. 


[23] Sawaki, A., Ohashi, Y., Omuro, Y., 2012. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the trastuzumab for gastric cancer (ToGA) study. Gastric Cancer, 15(3):313-322. 


[24] Seidman, A.D., Berry, D., Cirrincione, C., 2008. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 non-overexpressors: final results of cancer and Leukemia Group B Protocol 9840. J Clin Oncol, 26(10):1642-1649. 


[25] Slamon, D.J., Clark, G.M., Wong, S.G., 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235(4785):177-182. 


[26] Sorscher, S.M., 2011. Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer. Cancer Invest, 29(7):456-459. 


[27] Tierney, J.F., Stewart, L.A., Ghersi, D., 2007. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8(1):16


[28] Tokunaga, E., Oki, E., Nishida, K., 2006. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol, 11(3):199-208. 


[29] Wells, G.A., Shea, B., O'Connell, D., 2010. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. , (Available from )http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp,[Accessed on Sept. 2013],:

[30] Wolf-Yadlin, A., Kumar, N., Zhang, Y., 2006. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol, 2(1):54



Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE